Phoenix Biotech Acquisition Corp - Units (1 Ord Class A & 1/2 War)

Company Profile

Phoenix Biotech Acquisition Corp. is a newly organized blank check company incorporated as a Delaware corporation formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which the company refers to throughout this prospectus as its initial business combination or its business combination. To date, its efforts have been limited to organizational activities as well as activities related to this offering. Phoenix Biotech Acquisition Corp. has not selected any specific business combination target and the company has not, nor has anyone on its behalf, initiated any substantive discussions, directly or indirectly, with any business combination target. Phoenix Biotech Acquisition Corp. has generated no operating revenues to date, and the company may not generate operating revenues even after the company consummates its initial business combination. While Phoenix Biotech Acquisition Corp. may pursue an acquisition opportunity in any business, industry, sector or geographical location, the company intends to focus on industries that complement its management team’s background, and to capitalize on the ability of its management team to identify and acquire a business, focusing on the healthcare or healthcare related industries in the United States and Europe. In particular, Phoenix Biotech Acquisition Corp. intends to prioritize companies in the life sciences sector where its management team has extensive experience. Experienced SPAC Management Team with Business Combination Success. Joining its company is a team of high-level senior life sciences executives. The team includes Brian Atwood, who will serve as its Chairman immediately upon the effective date of this prospectus, Chris Ehrlich, its Chief Executive Officer, Douglas Fisher, MD, its President, and Daniel Geffken, its Chief Financial Officer. Its Board of Directors is expected to provide valuable guidance, technical domain expertise, value-added input regarding senior team leadership capabilities of prospective business combination targets, and have access to differentiated ideas and opportunities through complementary networks. They also have specific special purpose acquisition company, or SPAC, experience and a proven track record of business combination success.